Please login to the form below

Is the pharma business model ready for precision medicine?

Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges and opportunities while introducing the latest issue of 'Perspective' magazine on this weighty topic.
We are experiencing the dawn of precision medicine. With sales projected to rise to $141bn per annum between now and 2026, there can be no doubt that medicine is poised for the rapid acceleration of the precision era, which is why we have dedicated this edition of our ‘Perspective’ magazine to this weighty topic.

The promise of the precision medicine approach is well understood and often talked about. It exists at the convergence of genomic sequencing, biomarker research, bioinformatics and big data analysis.

In short, it promises improved outcomes for the patients identified as suitable for treatment.
In the era of precision medicine, greater response rates will reduce the human and economic cost of ineffective treatment. Couple this with a reduction in research and development expenditure, through smaller clinical trial costs and reduced time-to-market, which is estimated to save $26bn annually and the positive impact for all stakeholders becomes clear.

There can be no doubt that the levels of investment in precision medicine will fuel and accelerate its growth. From targeted therapeutics to diagnostic tools, from next-generation sequencing to data informatics, there has been an influx of capital and resultant innovation. The evidence is compelling. Precision medicine is gathering momentum. The question is: are we ready for it?

This is not an idle question. Across a broad spectrum of healthcare stakeholders, significant challenges remain, which need to be addressed for the full promise of precision medicine to be realised. As patient populations are stratified through increasingly sophisticated biomarker strategies, the challenges of identifying trial participants increases, as does the level of competition between trials for increasingly scarce patients.

Trial design is evolving to include so-called ‘basket’ designs, where the candidate drugs are matched to the somatic mutations found. This differs from traditional tumour type or ‘adaptive’ trials where the predictive biomarker is not clearly identified at trial commencement.

However, despite these developments, clinical trial recruitment remains difficult. Top of this list is patient recruitment, with a meagre 3% of potential patients volunteering to participate in oncology clinical trials. This challenge is being addressed through many approaches, one of which is discussed by Clinical Trail Connect later in this edition of our 'Perspective' magazine (download below).

Assuming the clinical trial is positive, the pharmaceutical company will experience a more complex launch that will likely include one or more partners, as well as an increase in the number of stakeholders to engage.

There is an often-quoted view that the precision of customer engagement should be enhanced to compliment this new approach to treating patients. As an organisation, Blue Latitude Health has built its business on this approach, spending the last 15 years developing tailored and personalised strategies for the commercialisation of products and services.

Yet although precise therapies are emerging, there will need to be more initiatives across the sector and major challenges remain.Medical organisations in pharma have been set up to support population medicine. However, the education they will undertake and the queries they will answer will become increasingly patient-specific. This will require medical organisations to adopt sophisticated one-to-one stakeholder engagement practices. They will also need access to larger and more complex data sets and to develop the analytical capability to analyse them.

Precision medicine is often presented as a panacea for patients and the headline benefit of better and more certain outcomes will doubtless help many. Dig beneath the surface, however, and challenges immediately present themselves.

The investment may be flowing and the science gathering pace, but there is still some way to go before we are properly ready for precision medicine.


Download the magazine from Blue Latitude Health

22nd May 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

The changing face of pharma in the precision era
Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to prepare to bring precision medicines to market and how she is ensuring the patient is consulted every step of the way.
Blue Latitude Health
Creative problem solving, solved
Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.
Blue Latitude Health
Three strategies for managing loss of exclusivity successfully
Claire Taylor, Senior Associate Consultant at Blue Latitude Health explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
Blue Latitude Health
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Blue Latitude Health
Diagnosing the lag in neuropsychiatric treatments
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health